Boehringer In­gel­heim scraps $600M+ lung can­cer pro­gram with Cure­Vac, as the biotech preps its sec­ond Covid-19 shot

The Ger­man biotech Cure­Vac re­leased its sec­ond quar­ter up­date Mon­day morn­ing, and dis­closed among the Covid-19 vac­cine high­lights that a $600 mil­lion-plus on­col­o­gy part­ner­ship with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER